Preclinical

Recently, there have been published reports stating that a large proportion of studies published in high-impact scientific journals could not be reproduced outside of the originator laboratories. These findings are particularly problematic since many of the drugs screened are being developed for human testing and ultimately FDA approval. Despite these reproducibility concerns, there is still...

Read more +

A sound preclinical plan coupled with expert oncology guidance can help identify biomarkers that can assist with patient selection—or help...

Read more +

Too often, new drugs fail during development due to poor study design and inadequate knowledge about the performance of a new drug. A large part of...

Read more +

If you’re exploring nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) or cancer-associated liver fibrosis, you may want...

Read more +

Ketogenic diets—which involve higher saturated fat, moderate protein and low carbohydrate consumption—have been successfully used to manage human...

Read more +

Often, new drug makers come across a potential anticancer agent—and as they consider evaluating that agent further, they tend to confront this...

Read more +

View More